ACTRN12610000238077
Completed
Phase 2
In critically ill patients with severe sepsis how does continuous beta-lactam infusion compared with intermittent beta-lactam dosing effect pharmacodynamics and clinical response to treatment? A pilot randomised controlled trial.
Beta-Lactam Infusion Group0 sites60 target enrollmentMarch 22, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Beta-Lactam Infusion Group
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Confirmed or suspected infection with new organ dysfunction
- •2\) Commencement within the previous 24 hours or planned commencement of ticarcillin/clavulanate, piperacillin/tazobactam or meropenem
- •3\) Expected or actual ICU stay greater than 48 hours
Exclusion Criteria
- •1\) Allergy or potential allergy to study medications
- •2\) Receiving palliative or supportive treatment only at the time of screening
- •3\) Receiving contrinuous renal replacement therapy
- •4\) No central venous catheter access with 3 or more lumens
- •5\) Receipt of the study drug of interest for \> 24 hours prior to enrolment
- •6\) Discharge from the ICU within 48 hours
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Optimising cefepime dosing in intensive care: the pharmacokinetics of extended (prolonged) infusions.ACTRN12609000069257The Alfred30
Completed
Not Applicable
Sepsis in India Prevalence StudyCTRI/2019/05/019125The George Institute for Global Health666
Completed
Not Applicable
Data Collection project on patients with severe sepsiswho received injection named UlinastatiHealth Condition 1: null- SepsisCTRI/2014/03/004470MedantaThe medicity134
Unknown
Not Applicable
Sepsis in the acutely ill patients in the emergency department.Sepsis, septic shock, septische shock.NL-OMON29613MC Utrecht2,000
Not yet recruiting
Phase 4
Efficacy and safety of a colistin loading dose, population pharmacokinetic-pharmacodynamic profiles and bacterial clearance rate in critically ill patients with extensively drug-resistant Acinetobacter baumanii (XDRAb) infectionsACTRN12613000862741Helmi B Sulaiman100